

---

**Walker ChandioK & Co LLP**

16th Floor, Tower III,  
One International Center,  
S B Marg, Prabhadevi (W),  
Mumbai - 400013  
Maharashtra, India  
T +91 22 6626 2600

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Rossari Biotech Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Rossari Biotech Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate and joint venture (refer Annexure 1 for the list of subsidiaries, associate and joint venture included in the Statement) for the quarter ended **31 December 2025** and the consolidated year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. We did not review the interim financial results of five subsidiaries included in the Statement, whose financial results reflect total revenues of ₹ 3,630.05 million and ₹ 11,066.19 million, total net profit after tax of ₹ 68.18 million and ₹ 284.88 million, total comprehensive income of ₹ 66.74 million and ₹ 279.97 million, for the quarter and nine-months period ended on 31 December 2025, respectively as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 4.37 million and ₹ 13.42 million and total comprehensive income of ₹ 4.33 million and ₹ 13.39 million, for the quarter and nine-months period ended on 31 December 2025, respectively, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Further, of these subsidiaries and associate, 1 subsidiary is located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their country and which have been reviewed by other auditors under generally accepted auditing standards applicable in their country. The Holding Company's management has converted the financial results of such subsidiary from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of this subsidiary is based on the review report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The Statement includes the interim financial information of five subsidiaries, which has not been reviewed by their auditors, whose interim financial information reflects total revenues of ₹ 10.59 million and ₹ 10.59 million, total net loss after tax of ₹ 6.81 million and ₹ 25.30 million, total comprehensive loss of ₹ 6.41 million and ₹ 23.72 million, for the quarter and nine-months period ended on 31 December 2025, respectively as considered in the Statement. The Statement also includes the Group's share of net profit/(loss) after tax of ₹ (0.35) million and ₹ 0.47 million, and total comprehensive income/(loss) of ₹ (0.35) million and ₹ 0.47 million for the quarter and nine-months period ended on 31 December 2025 respectively, in respect of a joint venture, based on its interim financial information, which have not been reviewed by its auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the aforesaid subsidiaries and joint venture, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

**For Walker Chandio & Co LLP**

Chartered Accountants

Firm Registration No: 001076N/N500013

**Bharat Shetty**

Partner

Membership No. 106815

**UDIN: 26106815XMWVNA4421**

**Place: Mumbai**

**Date: 17 January 2026**

**Rossari Biotech Limited**

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

**Annexure 1****List of entities included in the Statement**

<b>Sr. No.</b>	<b>Particulars</b>
	<b>Subsidiaries</b>
1	Buzil Rossari Private Limited
2	Rossari Consumer Products Private Limited
3	Unitop Chemicals Private Limited
4	Tristar Intermediates Private Limited
5	Rossari Bangladesh Limited
6	Rossari Global DMCC
7	Rossari International Company Limited
8	Rossari (Singapore) PTE. Ltd. (Incorporated on 18 December 2025)
	<b>Step down subsidiaries</b>
1	Rossari Biotech Trading FZE
2	Unistar Thai Co. Ltd
	<b>Joint Venture</b>
1	Hextar Unitop SDN BHD (Joint venture of Unitop Chemicals Private Limited)
	<b>Associate</b>
1	Romakk Chemicals Private Limited



**ROSSARI BIOTECH LIMITED**  
(AN ISO9001:2005 & 14001:2015 Certified Company)




Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079  
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025**

Particulars	Quarter ended			Nine months ended		Year Ended
	31st December, 2025	30th September, 2025	31st December, 2024	31st December, 2025	31st December, 2024	31st March, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>I INCOME</b>						
Revenue from operations	5,816.80	5,861.07	5,127.31	17,115.03	15,007.32	20,802.94
Other Income	5.09	16.04	5.51	33.13	22.18	40.09
<b>Total Income</b>	<b>5,821.89</b>	<b>5,877.11</b>	<b>5,132.82</b>	<b>17,148.16</b>	<b>15,029.50</b>	<b>20,843.03</b>
<b>II EXPENSES</b>						
Cost of materials consumed	4,175.99	4,072.12	3,214.75	11,592.10	9,298.73	12,996.44
Purchase of stock-in-trade	109.73	293.88	459.94	693.18	1,308.84	1,647.68
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(277.71)	(357.45)	(174.22)	(555.24)	(291.08)	(311.15)
Employee benefits expense	402.56	377.99	356.94	1,155.20	968.41	1,323.30
Finance costs	76.65	60.91	49.44	194.84	123.09	178.11
Depreciation and amortisation expenses	196.14	182.33	183.20	555.96	488.54	670.73
Other expenses	717.50	755.29	622.28	2,143.27	1,766.51	2,495.85
<b>Total Expenses</b>	<b>5,400.86</b>	<b>5,385.07</b>	<b>4,712.33</b>	<b>15,779.31</b>	<b>13,663.04</b>	<b>19,000.96</b>
<b>III Profit before Share of profit of joint venture, associate, exceptional items and tax [I-II]</b>	<b>421.03</b>	<b>492.04</b>	<b>420.49</b>	<b>1,368.85</b>	<b>1,366.46</b>	<b>1,842.07</b>
<b>IV Share of profit of joint venture and associate</b>	<b>3.98</b>	<b>4.68</b>	<b>3.32</b>	<b>13.87</b>	<b>8.33</b>	<b>9.78</b>
<b>V Profit before exceptional items and tax [III+IV]</b>	<b>425.01</b>	<b>496.72</b>	<b>423.81</b>	<b>1,382.72</b>	<b>1,374.79</b>	<b>1,851.85</b>
<b>VI Exceptional items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>VII Profit before tax [V-VI]</b>	<b>425.01</b>	<b>496.72</b>	<b>423.81</b>	<b>1,382.72</b>	<b>1,374.79</b>	<b>1,851.85</b>
<b>VIII Tax Expense</b>						
Current tax charge	132.08	160.51	144.24	453.64	446.52	590.71
Deferred tax (credit)	(34.81)	(32.55)	(37.45)	(103.38)	(91.07)	(102.64)
<b>Total Tax Expense</b>	<b>97.27</b>	<b>127.96</b>	<b>106.79</b>	<b>350.26</b>	<b>355.45</b>	<b>488.07</b>
<b>IX Profit after tax [VII-VIII]</b>	<b>327.74</b>	<b>368.76</b>	<b>317.02</b>	<b>1,032.46</b>	<b>1,019.34</b>	<b>1,363.78</b>
<b>X Other comprehensive income / (loss)</b>						
<b>A Items that will not be reclassified to profit or loss</b>						
i Remeasurements of the defined benefit plans	(2.87)	(3.41)	1.24	(9.38)	1.31	(12.67)
ii Income tax relating to items that will not be reclassified to profit or loss	0.72	0.86	(0.31)	2.36	(0.33)	3.18
<b>B Items that will be reclassified subsequently to profit or loss</b>						
i Exchange difference on translation of foreign operations	0.94	(0.09)	-	2.11	-	(0.76)
ii Income tax relating to items that will be reclassified to profit or loss	(0.53)	-	-	(0.53)	-	-
<b>Total other comprehensive income/(loss)</b>	<b>(1.74)</b>	<b>(2.64)</b>	<b>0.93</b>	<b>(5.44)</b>	<b>0.98</b>	<b>(10.25)</b>
<b>XI Total comprehensive income (IX + X)</b>	<b>326.00</b>	<b>366.12</b>	<b>317.95</b>	<b>1,027.02</b>	<b>1,020.32</b>	<b>1,353.53</b>
<b>Profit for the period/year attributable to</b>						
Owners of the Company	327.74	368.76	317.02	1,032.46	1,019.34	1,363.78
Non Controlling Interest	-	-	-	-	-	-
	<b>327.74</b>	<b>368.76</b>	<b>317.02</b>	<b>1,032.46</b>	<b>1,019.34</b>	<b>1,363.78</b>
<b>Other Comprehensive Income/(Loss) attributable to</b>						
Owners of the Company	(1.74)	(2.64)	0.93	(5.44)	0.98	(10.25)
Non Controlling Interest	-	-	-	-	-	-
	<b>(1.74)</b>	<b>(2.64)</b>	<b>0.93</b>	<b>(5.44)</b>	<b>0.98</b>	<b>(10.25)</b>
<b>Total Comprehensive Income attributable to</b>						
Owners of the Company	326.00	366.12	317.95	1,027.02	1,020.32	1,353.53
Non Controlling Interest	-	-	-	-	-	-
	<b>326.00</b>	<b>366.12</b>	<b>317.95</b>	<b>1,027.02</b>	<b>1,020.32</b>	<b>1,353.53</b>
Paid up equity share capital (Face value of Rs 2.00 per share)	110.76	110.73	110.71	110.76	110.71	110.73
Other equity	-	-	-	-	-	11,743.76
<b>Earnings per equity share (in Rs.)</b>						
Basic	5.92*	6.66*	5.73*	18.65*	18.44*	24.66
Diluted	5.91*	6.65*	5.72*	18.63*	18.41*	24.63

\*Not annualized



**Notes:**

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 17th January, 2026.
2. The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The consolidated financial results include the financial results of four foreign subsidiaries - Rossari Global DMCC, Rossari Bangladesh Limited, Rossari International Company Limited and Rossari (Singapore) Pte Ltd (incorporated on 18th December 2025), two step-down foreign subsidiaries - Rossari Biotech Trading FZE and Unistar Thai Co. Ltd. (100% subsidiary of Rossari Global DMCC), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. (a joint venture company of Unitop Chemicals Private Limited).
4. The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.
5. During the quarter ended 31st December, 2025, the Holding Company has allotted 14,400 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
6. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the 'New Labour Codes'). These codes have been made effective from 21st November, 2025.

The Group has estimated the revised gratuity liability as at 31st December 2025 as per the New Labour Codes and the additional liability arising thereon has been recognized as part of employee benefit expense in the current reporting period. No material additional liability on compensated absences and provident fund arose on account of the aforesaid codes. The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified.

7. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.

**For ROSSARI BIOTECH LIMITED**

Place : Mumbai  
Date : 17th January, 2026



**SUNIL CHARI**  
Managing Director  
DIN:00149083



**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Rossari Biotech Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Rossari Biotech Limited** ('the Company') for the quarter ended **31 December 2025** and year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Walker Chandio & Co LLP**

Chartered Accountants

Firm Registration No: 001076N/N500013

**Bharat Shetty**

Partner

Membership No. 106815

UDIN: 26106815SRUGWW8412

**Place: Mumbai**

**Date: 17 January 2026**

# ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)

Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079

T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818



## STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

Particulars	Quarter ended			Nine months ended		Rs. In million
	31st December, 2025	30th September, 2025	31st December, 2024	31st December, 2025	31st December, 2024	Year Ended 31st March, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>I INCOME</b>						
Revenue from operations	4,506.58	4,195.12	3,682.78	12,359.28	10,049.75	14,316.28
Other Income	11.41	13.97	10.06	42.80	33.46	57.42
<b>Total Income</b>	<b>4,517.99</b>	<b>4,209.09</b>	<b>3,692.84</b>	<b>12,402.08</b>	<b>10,083.21</b>	<b>14,373.70</b>
<b>II EXPENSES</b>						
Cost of materials consumed	2,749.25	2,508.67	2,098.05	7,375.35	5,524.45	8,111.17
Purchase of stock-in-trade	585.45	717.91	577.39	1,804.20	1,911.79	2,530.00
Changes in inventory of finished goods, work-in-progress and stock-in-trade	25.49	(142.09)	(13.08)	(23.20)	(123.65)	(170.42)
Employee benefit expenses	187.31	173.13	163.63	517.10	442.49	600.11
Finance costs	39.53	24.93	22.78	95.39	65.09	95.84
Depreciation and amortisation expenses	74.69	73.43	74.26	219.62	200.27	276.90
Other expenses	455.27	433.39	357.19	1,238.46	954.32	1,383.07
<b>Total Expenses</b>	<b>4,116.99</b>	<b>3,789.37</b>	<b>3,280.22</b>	<b>11,226.92</b>	<b>8,974.76</b>	<b>12,826.67</b>
<b>III Profit before exceptional items and tax [I-II]</b>	<b>401.00</b>	<b>419.72</b>	<b>412.62</b>	<b>1,175.16</b>	<b>1,108.45</b>	<b>1,547.03</b>
<b>IV Exceptional items</b>	-	-	-	-	-	-
<b>V Profit before tax [III-IV]</b>	<b>401.00</b>	<b>419.72</b>	<b>412.62</b>	<b>1,175.16</b>	<b>1,108.45</b>	<b>1,547.03</b>
<b>VI Tax Expense</b>						
Current tax charge	105.20	112.35	114.74	313.97	298.35	421.86
Deferred tax charge/(credit)	(10.46)	(5.12)	(8.43)	(19.89)	(13.68)	(22.25)
<b>Total Tax Expense</b>	<b>94.74</b>	<b>107.23</b>	<b>106.31</b>	<b>294.08</b>	<b>284.67</b>	<b>399.61</b>
<b>VII Profit after tax [V-VI]</b>	<b>306.26</b>	<b>312.49</b>	<b>306.31</b>	<b>881.08</b>	<b>823.78</b>	<b>1,147.42</b>
<b>VIII Other comprehensive income / (loss)</b>						
<b>A Items that will not be reclassified to profit or loss</b>						
i Remeasurements of the defined benefit plans	(0.94)	(0.93)	(0.04)	(2.81)	(0.12)	(3.75)
ii Income tax relating to items that will not be reclassified to profit or loss	0.23	0.23	0.01	0.70	0.03	0.94
<b>B Items that will be reclassified subsequently to profit or loss</b>	-	-	-	-	-	-
<b>Total other comprehensive income/(loss)</b>	<b>(0.71)</b>	<b>(0.70)</b>	<b>(0.03)</b>	<b>(2.11)</b>	<b>(0.09)</b>	<b>(2.81)</b>
<b>IX Total comprehensive income (VII + VIII)</b>	<b>305.55</b>	<b>311.79</b>	<b>306.28</b>	<b>878.97</b>	<b>823.69</b>	<b>1,144.61</b>
Paid up equity share capital (Face value of Rs 2 per share)	110.76	110.73	110.71	110.76	110.71	110.73
Other equity						10,661.01
<b>X Earnings per equity share (in Rs.)</b>						
Basic	5.53*	5.64*	5.53*	15.91*	14.90*	20.75
Diluted	5.53*	5.64*	5.53*	15.90*	14.88*	20.72

\*Not annualized



**Notes:**

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 17th January, 2026.
2. The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.
4. During the quarter ended 31st December, 2025, the Company has allotted 14,400 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
5. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the 'New Labour Codes'). These codes have been made effective from 21st November, 2025.

The Company has estimated the revised gratuity liability as at 31st December 2025 as per the New Labour Codes and the additional liability arising thereon has been recognized as part of employee benefit expense in the current reporting period. No material additional liability on compensated absences and provident fund arose on account of the aforesaid codes. The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified.

6. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.

**For ROSSARI BIOTECH LIMITED**



  
**SUNIL CHARI**  
Managing Director  
DIN:00149083

Place : Mumbai

Date : 17 January, 2026

